Regeneron: Full Analysis of Quarterly Results for Investors

Regeneron Pharmaceuticals is one of the most stable names in the American biotechnology industry, with a business model built on scientific depth and commercial discipline. The 2024 financial results confirm that the company is successfully managing the post-patent challenges of Eylea, while the expansion of Dupixent is performing the function of a new growth driver.